在mRNA COVID-19疫苗注射后出现疹风险
Ana Florea1, Jun Wu1, Lei Qian1
1Kaiser Permanente Southern California, Department of Research & Evaluation, Pasadena, CA, USA.
Expert review of vaccines
|July 7, 2023
概括
mRNA COVID-19 疫苗在第二剂后可能会略微增加疹病毒 (HZ) 的风险,特别是在未接种疹疫苗的50岁及以上的个人中.
科学领域:
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
- 流行病学 流行病学
背景情况:
- 在mRNA COVID-19疫苗接种后报告了不良事件.
- 疹疹 (HZ) 是其中一个报告的不良事件.
- 为了调查mRNA COVID-19疫苗接种和随后的HZ发展之间的关联,进行了一项研究.
研究的目的:
- 评估mRNA COVID-19疫苗接种与疹病毒 (HZ) 发病率之间的关联.
- 为了比较接种疫苗和未接种疫苗的个体在mRNA COVID-19疫苗注射后的HZ风险.
主要方法:
- 在南加州凯泽永久医院 (KPSC) 进行了一项队列研究.
- 接受mRNA COVID-19疫苗 (mRNA-1273和BNT162b2) 的人与未接种疫苗的人进行了匹配.
- 在随访后90天内,使用诊断代码和抗病毒处方确定了发生的HZ病例.
- 考克斯的比例危险模型被用来估计调整后的危险比率 (aHR).
主要成果:
- 该研究包括每种mRNA疫苗 (mRNA-1273和BNT162b2) 的100多万接种者和100多万未接种疫苗的对照者.
- 与未接种疫苗的个人相比,在第二剂mRNA-1273 (aHR: 1.14) 和BNT162b2 (aHR: 1.12) 后90天内观察到适度增加的HZ风险.
- 在没有先前接种疹疫苗的50岁及以上个体中,第二剂疫苗接种后HZ的aHR也增加了mRNA-1273 (aHR:1.18) 和BNT162b2 (aHR:1.15) 的aHR.
结论:
- 研究结果表明,在第二剂mRNACOVID-19疫苗接种后,疹风险可能会增加.
- 这种增加的风险似乎在50岁及以上未接种疹疫苗的人群中更为明显.
- 进一步的研究可能是有必要的,以了解这种关联背后的机制.
相关概念视频
Vaccinations
44.8K
Overview
44.8K
Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K
Cancer Vaccines
428
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
428
Cross-reactivity
31.3K
Overview
31.3K
Relative Risk
233
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
233
Factors Affecting the Risk of Infection
12.0K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
12.0K


